Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

November 10, 2022

https://www.globenewswire.com/news-release/2022/11/10/2553395/0/en/Scopus-BioPharma-s-Subsidiary-Duet-BioTherapeutics-Announces-Key-Scientific-Data-to-be-Presented-at-the-37th-Annual-Meeting-and-Exposition-of-the-Society-for-Immunotherapy-of-Cance.html

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer (“SITC”).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.